The typical concentration of naringin in grapefruit juice is around 400 mg/L. The reported
LD50 of naringin in rodents in 2000 mg/kg. Naringin
inhibits some drug-metabolizing
cytochrome P450 enzymes, including
CYP3A4 and
CYP1A2, which may result in drug-drug interactions. Ingestion of naringin and related flavonoids can also affect the intestinal absorption of certain drugs, leading to either an increase or decrease in circulating drug levels. To avoid interference with drug absorption and metabolism, the consumption of citrus (especially grapefruit) and other juices with medications is advised against. However,
in vitro studies have also shown that naringin in grapefruit is not what causes the inhibitory effects associated with grapefruit juice. Naringin solution when compared to grapefruit solution produced much less inhibition of
CYP3A4. Furthermore,
bitter orange juice, which contains considerably less naringin content than grapefruit juice, was found to produce the same level of inhibition of CYP3A4 as grapefruit juice. This would suggest that an inhibitor other than naringin, such as
furanocoumarin, which is also found in Seville oranges, may be at work. and in vitro studies have been unable to effectively convert naringin into naringenin. This leaves open the possibility that in vivo, naringin converted into naringenin by naringinase is what causes the inhibitory effect on CYP3A4. Due to the contradictory results of the effect of naringin it is hard to tell whether it is naringin itself or other components of grapefruit juice that cause
drug-drug interaction and lead to its toxicity. == Uses==